Transparency Market Research has published a new report on the global diagnostic testing of STDs market. According to the report, the global diagnostic testing of STDs market is expected to progress from US$65.9 bn in 2012 to US$108.5 bn by 2019. The report, titled ‘Diagnostic Testing of STDs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,’ states that the global market is expected to expand at an 8.10% CAGR during the period between 2013 and 2019. Factors such as the rising prevalence of STDs, the implementation of national screening programs, and favorable reimbursement policies are expected to propel the global diagnostic testing of STDs market in the years to come.
Sexually transmitted diseases (STDs) spread primarily because of person-to-person sexual contact. There are many techniques used to diagnose sexually transmitted diseases. Undiagnosed STDs may have many critical implications on maternal, reproductive, and newborn health. For example, 10% to 15% of women suffering from untreated Chlamydia infection have the possibility of developing a symptomatic pelvic inflammatory disease. Untreated and undiagnosed sexually transmitted diseases such as syphilis could lead to congenital syphilis, which is associated with the high risk of pre-term birth. The prenatal spread of herpes simplex virus infection is associated with a high risk of various neurological problems and even death. Untreated and undiagnosed STDs increase the risk of acquisition and transmission of HIV. The timely diagnosis of STDs is imperative to prevent the transmission of STDs and reduce the risk of sexually transmitted infections.
Factors such as the presence of many STD-affected people in out-of-reach areas, stringent government regulations, and the stigma associated with voluntary STD testing are predicted to hamper the growth of the global diagnostic testing of STDs market in the coming few years. The increasing number of national screening programs across countries is likely to create opportunities for POC and laboratory test providers. The reduction in the number of visits to specialized GUM and STD clinics is creating many opportunities for private and public labs. All these factors are predicted to create growth opportunities in the global diagnostic testing of STDs market in the coming few years.
The global diagnostic testing of STDs market is segmented on the basis of region, location, and type. Based on type, the global diagnostic testing of STDs market is classified into herpes simplex virus (HSV) testing, chancroid testing, humap papilloma virus (HPV) testing, HIV testing, P&S syphilis testing, chlamydia testing, and gonorrhea testing. Every year, approximately 300,000 cervical cancer deaths are registered, occurring due to HPV. The HPV testing segment is expected to expand at a 70% CAGR during the period between 2013 and 2019. By location, the global diagnostic testing of STDs market is classified into lab testing and point-of-care testing.
Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1631
Geographically, the global diagnostic testing of STDs market is divided into Asia Pacific, Europe, North America, and Rest of the World. Currently, North America dominates the global diagnostic testing of STDs market due to the growing prevalence of diseases such as gonorrhea, P&S syphilis, and chlamydia. In terms of testing volume, the Asia Pacific diagnostic testing of STDs market is expected to register steady growth in the years to come.
bioMerieux, Becton Dickinson & Company, Hologic. Inc., Danaher Corporation, and Roche Holding are some of the prominent companies operating in the global diagnostic testing of STDs market.